Search clinical trials for: Gut hormones, single nucleotide variants (SNVs), GIP, GLP-1, GLP-2

Total 92413 results

Gan and Lee Pharmaceuticals, USA

Active, not recruiting

A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

China
German Institute of Human Nutrition
Beneo GmbH

Completed

Isomaltulose VS Sucrose - Postprandial Effect on Incretin Profile and Second Meal Effect

Diabetes Mellitus, Type 2 | Metabolic Syndrome

Germany
Ludwig-Maximilians - University of Munich
Merck Sharp & Dohme LLC

Completed

Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Pichamol Jirapinyo, MD, MPH

Not yet recruiting

ESG vs GLP-1RA vs ESG + GLP-1RA in Patients With Obesity, NAFLD and Advanced Fibrosis: A Randomized Controlled Trial

Liver Diseases | Metabolic Diseases | Obesity | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Insulin Resistance | Weight Loss | Liver Fat | NAFLD | Insulin Sensitivity/Resistance | Insulin Sensitivity | Liver Fibrosis | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non Alcoholic Fatty... and other conditions

United States
Johns Hopkins University

Terminated

The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition

Bariatric Surgery

United States
University of Athens

Recruiting

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

Diabetes Mellitus, Type 2

Greece
Akdeniz University

Recruiting

Assesment of Embryo Viability and Re-expansion After Thawing in Blastocyst Stage Embryos

Infertility

Turkey
Indonesia University

Completed

The Effect of Andrographis Paniculata to GLP-1, Fasting Insulin, Insulin 2-h Post OGTT, and HOMA-IR

Increased Insulin

Indonesia
Sanofi

Completed

Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Canada, Brazil, Poland, Romania, Russian Federation, Ukraine
St. Luke's-Roosevelt Hospital Center
National Institutes of Health (NIH)

Withdrawn

Mechanisms of Diabetes Control After Weight Loss Surgery, Sub-study #1

Type 2 Diabetes | Gastric Bypass Surgery | Gastric Banding

United States
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute

Recruiting

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes (PRECIDENTD)

Type2Diabetes | ASCVD

United States
AstraZeneca

Completed

PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure

Congestive Heart Failure

United States
University of Minnesota

Completed

GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

Obesity, Morbid

United States
Hoffmann-La Roche

Completed

A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Diabetes Mellitus Type 2

Australia, United States, France, Germany, Mexico, Puerto Rico, Peru
University Hospital, Gentofte, Copenhagen
Merck Sharp & Dohme LLC

Completed

Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Denmark
Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Recruiting

Talocalcaneal Angle in Calcaneal Spur Formation

Plantar Fascitis | Foot Callus

Turkey
Diabeteszentrum Bad Lauterberg im Harz

Completed

The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP

Type 2 Diabetes
Sanofi

Completed

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (GAUDI)

Type 2 Diabetes Mellitus

Japan
Tel Aviv University
Zohar Landau; Shani Tsameret

Unknown

Influence of Dairy Protein Breakfast on Glycemia, Weight Loss and Clock Genes in T2D (Mdiet)

Type2 Diabetes | Healthy Obesity, Metabolically

Israel
University Hospital, Gentofte, Copenhagen

Completed

Importance of Meal Fat Content and Gall Bladder Emptying for Postprandial GLP-1 Secretion in Type 2 Diabetes Patients

Diabetes

Denmark
Zuyderland Medisch Centrum
Nederlandse Obesitas Kliniek

Withdrawn

Liraglutide for Low-responders After Bariatric Surgery (LIBAR)

Obesity | Obesity, Morbid
University of Texas Southwestern Medical Center
UT Southwestern Nutrition Obesity Research Center

Recruiting

Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation

Obesity

United States
University of Washington
Eli Lilly and Company; Sanofi; Bayer; US Department of Veterans Affairs; University... and other collaborators

Completed

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (FLAT-SUGAR)

Type 2 Diabetes

United States
University of California, Los Angeles
Amylin Pharmaceuticals, LLC.

Completed

Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women

Obesity

United States
Profil Institut für Stoffwechselforschung GmbH

Completed

Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment

Diabetes Mellitus

Germany
Glostrup University Hospital, Copenhagen
University of Copenhagen; European Foundation for the Study of Diabetes

Completed

Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Tolerance

Insulin Resistance | Inactivity | Deteriorated Glucose Homeostasis

Denmark
University of Minnesota

Completed

Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity

Severe Obesity

United States
Yaounde Central Hospital
University of Yaounde 1; University of Buea

Completed

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes (LIRAVIS)

Type 2 Diabetes Mellitus

Cameroon
Nanjing First Hospital, Nanjing Medical University

Recruiting

Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

Diabetes

China
Assistance Publique Hopitaux De Marseille

Completed

Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics

Obesity | Diabetes

France
University Hospital, Gentofte, Copenhagen
Zealand Pharma

Completed

GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake (GASOLIN II)

Type 2 Diabetes Mellitus | Overweight and Obesity

Denmark
University Hospital, Gentofte, Copenhagen
Sanofi

Completed

Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota

Type 2 Diabetes

Denmark
University of Oulu
Turku University Hospital; Oulu University Hospital; Tampere University Hospital and other collaborators

Completed

Incretin-based Therapy in Early Diagnosed Type 1 Diabetes

Type 1 Diabetes

Finland, Sweden
GlaxoSmithKline

Completed

Glucagon-like Peptide (GLP) Utilization and Safety

Diabetes Mellitus, Type 2
Universitaire Ziekenhuizen KU Leuven
Jessa Hospital; Universitair Ziekenhuis Brussel; University Hospital, Antwerp; AZ... and other collaborators

Recruiting

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes (SERENA)

Glucose Intolerance After a Recent History of Gestational Diabetes

Belgium
University of Maryland, Baltimore

Recruiting

Pharmacogenetics of Response to GLP1R Agonists (PORT)

Obesity | Diabetes Type 2

United States
McGill University Health Centre/Research Institute...

Active, not recruiting

Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care (SEMA-AP)

Diabetes Mellitus, Type 1 | Type 1 Diabetes

Canada
St. Luke's-Roosevelt Hospital Center
National Institutes of Health (NIH)

Completed

Effect of Meal Number, Frequency, and Form on Satiety and Metabolism After Weight Loss Surgery

Obesity | Gastric Bypass Surgery

United States
University of California, Davis
Knownwell

Recruiting

CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users

Obesity

United States
University of Oulu
Turku University Hospital; Oulu University Hospital; Tampere University Hospital

Enrolling by invitation

Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults

Type 1 Diabetes

Finland
Gan and Lee Pharmaceuticals, USA

Completed

A Study of GZR18 Injection in Chinese Obese/Overweight Patients

Obesity | Overweight

China
Medical University of South Carolina

Recruiting

GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy

Gastric Content Aspiration

United States
Aga Khan University
Rehman Medical Institute - RMI

Recruiting

"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."

Diabetes Mellitus, Type 2 | Weight Change, Body

Pakistan
Xiangya Hospital of Central South University

Recruiting

Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

Obesity

China
Oxford Brookes University
Roquette Frères

Completed

Glycaemic Response, Insulinaemic Response, GLP-1 and GIP Testing of Food Product Lines

Healthy

United Kingdom
University of Alabama at Birmingham
Amylin Pharmaceuticals, LLC.

Terminated

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist (CMBD)

Type 2 Diabetes Mellitus | Bone Remodeling

United States
Xiang Guang-da

Completed

GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men

Obesity

China
University Medical Centre Ljubljana

Completed

PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome

Obesity | PCOS

Slovenia
University Hospital, Gentofte, Copenhagen
Novo Nordisk A/S; University of Copenhagen

Completed

The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)

Maturity-onset Diabetes of the Young

Denmark
Gan and Lee Pharmaceuticals, USA

Completed

A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes

China

Search clinical trials for: Gut hormones, single nucleotide variants (SNVs), GIP, GLP-1, GLP-2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations